| ¿µ¹® | histamine | ÇÑ±Û | È÷½ºÅ¸¹Î |
|---|---|---|---|
| ¼³¸í | È÷½ºÅ¸¹ÎÀ̶õ ºñ¸¸¼¼Æ÷°ú È£¿°±â±¸¶ó´Â ¼¼Æ÷¿¡ ¸¹ÀÌ ÀÖ´Â ¹°Áú·Î½á ±â´ÉÀº ´ÙÀ½°ú °°´Ù. 1. ¸ð¼¼Ç÷°üÀÇ À̿ϰú Åõ°ú¼ºÀÇ Áõ°¡ 2. ³»Àå¿¡ ºÐÆ÷ÇÏ´Â ±ÙÀ°ÀÇ ¼öÃà 3. À§»êÀÇ ºÐºñÃËÁø 4. ½ÉÀå¹Úµ¿¼öÀÇ Áõ°¡ È÷½ºÅ¸¹ÎÀÌ ºÐºñµÇ¾î ´Ù¸¥ ¼¼Æ÷¿¡ ¿µÇâÀ» ÁÖ¾î À§¿Í °°Àº ¿ªÇÒÀ» ÇÏ·Á¸é ¹Ýµå½Ã ¼¼Æ÷Ç¥¸é¿¡ ÀÖ´Â È÷½ºÅ¸¹Î ¼ö¿ëü¿Í °áÇÕÀ» ÇÏ¿©¾ßÇÑ´Ù. ÀÌ È÷½ºÅ¸¹Î ¼ö¿ëü¿¡´Â µÎ °¡Áö°¡ ÀÖ´Ù. Çϳª´Â H1-¼ö¿ëü¶ó°í ÇÏ´Â °ÍÀε¥ ÀÌ ¼ö¿ëü´Â À§ÀÇ ÀÛ¿ëÁß¿¡¼ 1, 2¹øÀÇ ÀÛ¿ëÀ» ¸Å°³ÇÑ´Ù. Áï H1-¼ö¿ëü¿¡ È÷½ºÅ¸¹ÎÀÌ ºÎÂøÇÒ ¶§¿¡ À§ÀÇ 1, 2¹ø°ú °°Àº ÀÛ¿ëÀÌ ÀϾÙ. ´Ù¸¥ Çϳª´Â H2-¼ö¿ëü¶ó°í ÇÏ´Â °ÍÀε¥ 3, 4¹øÀÇ ÀÛ¿ëÀ» ¸Å°³ÇÑ´Ù. ±×¸®°í ¾ÈƼÈ÷½ºÅ¸¹Îµµ °¢°¢ H1-¼ö¿ëü¿¡ ÀÛ¿ëÇÏ´Â °ÍÀÌ ÀÖ°í, H2-¼ö¿ëü¿¡ ÀÛ¿ëÇÏ´Â °ÍÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | rheumatoid factor | ÇÑ±Û | ·ù¸¶Æ¼½º ÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | IgGÀÇ FcºÎÀ§¿¡ ÀÖ´Â Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼ ÀüÇüÀûÀÎ ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) ȯÀÚÀÇ 80%¿¡¼ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀÚ´Â IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁÖ·Î IgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇÏ´Â ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù |
||
| ¿µ¹® | growth factor | ÇÑ±Û | ¼ºÀåÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ ºÐÈ ¹× ¼ºÀå¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú. ¼ºÀåÀÎÀÚ´Â Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ žÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù. |
||
| ¿µ¹® | risk factor | ÇÑ±Û | À§ÇèÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î äÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ ÀÖ¾î¼ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» ÇÏ¸é¼ ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£3/SvÀÌ´Ù. |
||
| HSF | heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase... |
|---|---|
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| HSF | Histamine sensitizing factor |
|---|---|
| HRF | Histamine Releasing Factor |
| 4-MH | 4-methyl histamine |
| H | Histamine |
| H2 | Histamine |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| radiation-sensitizing agents | Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (12 Dec 1998) |
|---|---|
| sensitizing dose | In experimental anaphylaxis, the antigenic inoculum that renders an animal susceptible (sensitive) to anaphylactic shock following a subsequent inoculum (shocking dose) of the same antigen (anaphylactogen). (05 Mar 2000) |
| sensitizing injection | An injection that sensitises a person so that subsequent exposure to the antigen (allergen) evokes an allergic response. (05 Mar 2000) |
| sensitizing substance | Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis. Synonym: CF antibody, sensitizing substance. (05 Mar 2000) |
| augmented histamine test | A test for maximal production of gastric acidity or anacidity; after preliminary administration of an antihistamine, histamine acid phosphate is injected subcutaneously in a dose of 0.04 mg/kg of body weight, followed by analysis of gastric contents. Synonym: augmented histamine test. (05 Mar 2000) |
| receptors, histamine | Cell-surface proteins that bind histamine and trigger intracellular changes influencing the behaviour of cells. Histamine receptors are widespread in the central nervous system and in peripheral tissues. Three types have been recognised and designated h1, h2, and h3. They differ in pharmacology, distribution, and mode of action. (12 Dec 1998) |
| receptors, histamine h1 | A class of histamine receptors discriminated by their pharmacology and mode of action. most histamine h1 receptors operate through the inositol phosphate/diacylglycerol second messenger system. Among the many responses mediated by these receptors are smooth muscle contraction, increased vascular permeability, hormone release, and cerebral glyconeogenesis. (12 Dec 1998) |
| receptors, histamine h2 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h2 receptors act via g-proteins to stimulate adenylate cylase. Among the many responses mediated by these receptors are gastric acid secretion, smooth muscle relaxation, inotropic and chronotropic effects on heart muscle, and inhibition of lymphocyte function. (12 Dec 1998) |
| receptors, histamine h3 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h3 receptors were first recognised as inhibitory autoreceptors on histamine-containing nerve terminals and have since been shown to regulate the release of several neurotransmitters in the central and peripheral nervous systems. (12 Dec 1998) |
| histamine | <biochemistry> Formed by decarboxylation of histidine. Potent pharmacological agent acting through receptors in smooth muscle and in secretory systems. Stored in mast cells and released by antigen. (See hypersensitivity). Responsible for the early symptoms of anaphylaxis. Also present in some venoms. (18 Nov 1997) |
| histamine agents | Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells. (12 Dec 1998) |
| histamine agonist | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (12 Dec 1998) |
| histamine antagonists | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonist. Classical antihistaminics block the histamine h1 receptors only. (12 Dec 1998) |
| histamine-fast | Indicating the absence of the normal response to histamine, especially in speaking of true gastric anacidity. (05 Mar 2000) |
| histamine flush | Vasodilatation and erythema occurring as a result of release of histamine; thought to be a factor in genesis of flush of carcinoid syndrome. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|